Unique ID issued by UMIN | UMIN000009694 |
---|---|
Receipt number | R000011363 |
Scientific Title | Effects of a 12-week whole body vibration training in Type 2 Diabetes in a primary healthcare setting. A Randomized Controlled Trial |
Date of disclosure of the study information | 2013/01/05 |
Last modified on | 2013/01/04 20:17:04 |
Effects of a 12-week whole body vibration training in Type 2 Diabetes in a primary healthcare setting. A Randomized Controlled Trial
Whole body vibration training in Type 2 Diabetes
Effects of a 12-week whole body vibration training in Type 2 Diabetes in a primary healthcare setting. A Randomized Controlled Trial
Whole body vibration training in Type 2 Diabetes
Europe |
Type 2 Diabetes
Endocrinology and Metabolism | Rehabilitation medicine |
Others
NO
To test the feasibility, safety and effectiveness of a 12-wk WBV intervention on glycemic control, lipid-related cardiovascular risk factors, quality of life, blood flow, balance and functional capacity among T2DM patients in a primary care context
Efficacy
Confirmatory
Pragmatic
Not applicable
Glycated hemoglobin -HbA1c-,
Quality of life, Blood flow, balance, fasting blood glucose, lipid-related cardiovascular risk factors (i.e. cholesterol, triglycerides, HDL, LDL, LDL/HDL and atherogenic index) and functional capacity as measured by time up and go -TUG- test, 6-minute walking test-T6MW and 30s-sit to stand-30s-STS- test
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
No treatment
NO
NO
Institution is not considered as adjustment factor.
NO
Numbered container method
2
Treatment
Device,equipment |
Whole body vibration group (WBV) which will perform a 12-week WBV-based program on an oscillating platform (12-16 Hz; 4 mm; 3 sessions a week) or usual-care control group (CON).
Whole body vibration group (WBV) which will perform a 12-week WBV-based program on an oscillating platform (12-16 Hz; 4 mm; 3 sessions a week) or usual-care control group (CON).
Not applicable |
Not applicable |
Male and Female
Eligible participants had to have T2DM confirmed by a primary care provider and based on the ADA diagnostic criteria
Exclusion criteria include history or evidence of advanced cardiovascular, renal or hepatic diseases, diabetic retinopathy, nephropathy or neuropathy, insulin use, orthopedic or other limitations that may interfere with their ability to exercise safely. Participants with HbA1c >10% also will be omitted. Moreover, participants receiving physical therapy will be excluded to avoid possible interactions with the present trial
60
1st name | |
Middle name | |
Last name | Borja Sañudo |
University of Seville
Department of Physical Education and Sport
Pirotecnia s/n
+81-034652387090
1st name | |
Middle name | |
Last name | Borja Sañudo |
University of Seville
Department of Physical Education and Sport
Pirotecnia s/n
+81-034652387090
bsancor@us.es
University of Seville
University of Seville
Self funding
NO
University of Seville(Spain)
2013 | Year | 01 | Month | 05 | Day |
Unpublished
Terminated
2011 | Year | 05 | Month | 15 | Day |
2012 | Year | 09 | Month | 15 | Day |
2012 | Year | 12 | Month | 15 | Day |
2013 | Year | 01 | Month | 04 | Day |
2013 | Year | 01 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011363